Search results
Results from the WOW.Com Content Network
Following promising phase 1 testing, Mayo Clinic is launching phase 2 of a randomized clinical trial of stem cell treatment for patients with severe spinal cord injury. The clinical trial, known as CELLTOP, involves intrathecal injections of autologous adipose-derived stem cells.
Mayo Clinic researchers have demonstrated the safety and potential benefit of stem cell regenerative medicine therapy for patients with subacute and chronic spinal cord injury. The results of the phase 1 Clinical Trial of Autologous Adipose-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury, known ...
This review briefly summarizes the pathophysiology of SCI and the therapeutic potential of stem cells and reviews published clinical trials with a specific focus on the different methodologies used in order to highlight unsolved issues in the treatment of SCI using a stem cell approach.
The present review focuses on SCI stem cell therapy, including bone marrow mesenchymal stem cells, umbilical mesenchymal stem cells, adipose-derived mesenchymal stem cells, neural stem cells, neural progenitor cells, embryonic stem cells, induced pluripotent stem cells, and extracellular vesicles.
Stem cell therapy has emerged as a promising strategy to promote the regeneration and repair of damaged neural tissue following SCIs.
Therapies based on transplantation of cells (ie, mature cells) or stem cells (ie, undifferentiated cells or partly differentiated cells that can differentiate and proliferate) are among the most promising strategies for the treatment of spinal cord injury.
The present review focuses on SCI stem cell therapy, including bone marrow mesenchymal stem cells, umbilical mesenchymal stem cells, adipose-derived mesenchymal stem cells, neural stem cells, neural progenitor cells, embryonic stem cells, induced pluripotent stem cells, and extracellular vesicles.
Stem cell-based regenerative therapy has opened an avenue for functional recovery of patients with spinal cord injury (SCI). Regenerative rehabilitation is attracting wide attention owing...
Mayo Clinic is enrolling patients in a clinical trial of adipose stem cell treatment for spinal cord injury caused by trauma. Participants will receive intrathecal injections of adipose-derived mesenchymal stem cells. No surgery or implantable medical device is required.
Therefore, stem cell therapy has attracted great attention as a treatment strategy for SCI. Stem cell therapy has shown great progress in preclinical research. Moreover, it has shown high therapeutic efficacy in other conditions, such as hematological malignancies, burns, and corneal transplants.